PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29544454-4	2018	The Food and Drug Administration (FDA)-approved anti-helminthic drug niclosamide is known to intervene in the Wnt/beta-catenin pathway signaling, leading to reduced expression of S100A4 linked to restricted in vivo metastasis formation.	Niclosamide	69-80	S100 calcium binding protein A4	Homo sapiens	179-185	
27127879-0	2016	S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.	Niclosamide	153-164	S100 calcium binding protein A4	Homo sapiens	0-6	
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	S100 calcium binding protein A4	Homo sapiens	37-43	
27127879-8	2016	Niclosamide, a reported inhibitor of S100A4, blocks expression and function of S100A4 with a reduction in proliferation, invasion and NF-kappaB-mediated MMP9 expression.	Niclosamide	0-11	S100 calcium binding protein A4	Homo sapiens	79-85	
34118929-0	2021	Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.	Niclosamide	22-33	S100 calcium binding protein A4	Homo sapiens	10-16	
34118929-4	2021	METHODS: Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide.	Niclosamide	264-275	S100 calcium binding protein A4	Homo sapiens	205-211	
34118929-4	2021	METHODS: Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide.	Niclosamide	264-275	S100 calcium binding protein A4	Homo sapiens	231-237	
31623154-0	2019	The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis.	Niclosamide	37-48	S100 calcium binding protein A4	Homo sapiens	4-10	
31623154-4	2019	We found that S100A4 was strongly up-regulated in reactive microglia and that niclosamide prevented NADPH oxidase 2, mTOR (mammalian target of rapamycin), and NF-kappaB (nuclear factor-kappa B) increase, cytoskeletal rearrangements, migration, and phagocytosis.	Niclosamide	78-89	S100 calcium binding protein A4	Homo sapiens	14-20	
31581665-6	2019	A repurposing S100A4 inhibitor, niclosamide, was found to reverse the HMGA2-driven gene signature both in colorectal cancer cell lines and patients" tissues.	Niclosamide	32-43	S100 calcium binding protein A4	Homo sapiens	14-20